You are here: Industry Insights > SARS-CoV-2

News List

Fluvoxamine may prevent severe COVID-19 onset, suggests trial europeanpharmaceuticalreview
November 17, 2020
Researchers say the promising results warrant larger trials evaluating fluvoxamine as a potential intervention to prevent COVID-19 patients developing severe symptoms.
£12.2m boost for coronavirus genomic surveillance pharmatimes
November 17, 2020
The COVID-19 Genomics UK (COG-UK) Consortium is being given £12.2 million from the Department for Health and Social Care Testing Innovation Fund to expand whole genome sequencing of positive SARS-CoV-2 virus samples.
Mesa Biotech Receives $13 Million from HHS to Develop 30 Minute SARS-CoV-2 & Flu A/Flu B Test americanpharmaceuticalreview
November 17, 2020
Mesa Biotech has been awarded a contract up to $13 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human ...
Fluvoxamine may prevent serious illness in COVID-19 patients worldpharmanews
November 16, 2020
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of ...
Quansys Biosciences Receives EUA for SARS-CoV-2 IgG Antibody Test americanpharmaceuticalreview
November 16, 2020
Quansys Biosciences announced the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its laboratory-based IgG antibody test.
OSE Provides Update on COVID-19 Vaccine americanpharmaceuticalreview
November 16, 2020
OSE Immunotherapeutics has announced successful completion of its human ex vivo study with CoVepiT, a prophylactic vaccine based on optimized epitopes selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that ..
Medigen, BlueWillow collaborate to develop SARS-CoV-2 intranasal vaccine pharmaceutical-business-review
November 12, 2020
Medigen Vaccine Biologics (MVC) has collaborated with BlueWillow Biologics for the development of intranasal vaccine for SARS-CoV-2, the novel coronavirus responsible for Covid-19 disease.
RNA structures of coronavirus reveal potential drug targets worldpharmanews
November 11, 2020
The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.
Pfizer, BioNTech Announce COVID-19 Vaccine Demonstrates Efficacy in Phase 3 Analysis americanpharmaceuticalreview
November 11, 2020
Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy ...
Indian researchers develop vaccine strategies for SARS-CoV-2, HIV viruses pharmaceutical-technology
November 11, 2020
Researchers at Indian Institute of Science’s (IISc) Molecular Biophysics Unit have announced the development of effective vaccine strategies against the SARS-CoV-2 and HIV viruses that cause Covid-19 and AIDS, respectively.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page